enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.50. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a research report on Saturday, September 27th. Get enGene alerts:Check Out Our Latest Stock Report on ENGNenGene Trading Down 4.8%NASDAQ ENGN opened at $7.75 on Thursday. enGene Company Profile(Get Free Report)enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.